Expert Opinion on Pharmacotherapy最新文献

Persisting challenges for antioxidants use in treatment of male infertility. 抗氧化剂用于治疗男性不育症的持续挑战。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-19 DOI: 10.1080/14656566.2026.2749640

Eslam M Eldamnhoury, Ahmed I El-Sakka

{"title":"Persisting challenges for antioxidants use in treatment of male infertility.","authors":"Eslam M Eldamnhoury, Ahmed I El-Sakka","doi":"10.1080/14656566.2026.2749640","DOIUrl":"https://doi.org/10.1080/14656566.2026.2749640","url":null,"abstract":"Introduction: Oxidative stress {OS} has emerged as a major etiological factor to male infertility and is present in significant proportion of subfertile patients classified as Male Oxidative Stress Infertility. This review aimed to critically evaluate the current challenges associated with the use of antioxidants in the management of male infertility.Areas covered: This manuscript was conducted using review of literature addressing oxidative stress, antioxidant therapy, diagnostic biomarkers, sperm DNA damage, assisted reproductive technologies {ART}, and clinical outcomes in male infertility. Review was conducted using PubMed, Scopus, and Web of Science to identify relevant studies published from January 2000 to March 2026, with emphasis on systematic reviews, randomized controlled trials and clinical guidelines. The evidence was critically evaluated across several major challenges that were identified and analyzed, including oxidative stress assessment, antioxidant mechanisms, diagnostic standardization, patient selection, treatment protocols, reductive stress, bioavailability, outcome measures, long-term safety, ART interactions, and publication bias. Major barriers that contribute to the inconsistency in the outcome of antioxidants use include the absence of standardized diagnostic criteria for oxidative stress, lack of consensus regarding antioxidant formulations and dosages, heterogeneity among clinical trials, and the risk of reductive stress resulting from excessive supplementation.Expert opinion: Despite the biological rationale supporting antioxidant therapy in male infertility, substantial challenges continue to limit its evidence-based clinical application. Future research should prioritize standardized diagnostic approaches, biomarker-guided patient selection, optimization of dosage and treatment duration, and assessment of clinically relevant reproductive outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current perspectives on targeted and combination pharmacotherapy for low-grade serous ovarian cancer. 低级别浆液性卵巢癌的药物联合治疗现状。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-18 DOI: 10.1080/14656566.2026.2749642

Orazio De Tommasi, Namrata Sethi, Stefania Bellone, Cem Demirkiran, Tobias M P Hartwich, Oda Fløtre Kvile, Kathrine Cooke, Stirling Wallace, Alessandro D Santin

{"title":"Current perspectives on targeted and combination pharmacotherapy for low-grade serous ovarian cancer.","authors":"Orazio De Tommasi, Namrata Sethi, Stefania Bellone, Cem Demirkiran, Tobias M P Hartwich, Oda Fløtre Kvile, Kathrine Cooke, Stirling Wallace, Alessandro D Santin","doi":"10.1080/14656566.2026.2749642","DOIUrl":"10.1080/14656566.2026.2749642","url":null,"abstract":"Introduction: Low-grade serous ovarian carcinoma (LGSOC) is a rare, frequently relapsing ovarian cancer characterized by relative chemoresistance, hormone-receptor expression, and recurrent activation of the RAS/RAF/MEK/ERK pathway.Areas covered: This narrative review examines the therapeutic vulnerabilities that are reshaping systemic treatment in LGSOC. PubMed/MEDLINE and Embase were searched from database inception through July 2026, supplemented by clinical-trial registries and regulatory sources. Endocrine dependence can be targeted with aromatase inhibitors and, increasingly, through combined estrogen-receptor and CDK4/6 blockade. MAPK signaling represents the principal molecular vulnerability: trametinib provides the strongest randomized evidence in recurrent disease, while avutometinib plus defactinib is approved in the United States for previously treated KRAS-mutated LGSOC. The review also considers the evolving role of chemotherapy, antiangiogenic therapy, and molecular biomarkers in treatment selection.Expert opinion: The therapeutic landscape is moving from empiric chemotherapy toward biologically informed treatment. The main challenge is now to define the optimal sequence of endocrine, MAPK-directed, and cell-cycle-targeted therapies according to disease tempo, molecular profile, required tumor shrinkage, prior exposure, and cumulative toxicity. Emerging strategies include combined pathway inhibition, chemotherapy-sparing endocrine regimens, and antibody-drug conjugates directed against FRα and TROP2. Their future integration will require prospective biomarker validation and direct comparison with established active treatments.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-16"},"PeriodicalIF":3.4,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal stromal tumors: can we do better than sunitinib in the second line? 胃肠道间质肿瘤:我们能做得更好在第二行舒尼替?

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-18 DOI: 10.1080/14656566.2026.2750247

Piotr Rutkowski, Anna Klimczak

{"title":"Gastrointestinal stromal tumors: can we do better than sunitinib in the second line?","authors":"Piotr Rutkowski, Anna Klimczak","doi":"10.1080/14656566.2026.2750247","DOIUrl":"10.1080/14656566.2026.2750247","url":null,"abstract":"Introduction: Advances in understanding the molecular mechanisms have led to the development of targeted therapies, which transformed the treatment of gastrointestinal stromal tumor (GIST). Sunitinib is an oral, multi-targeted tyrosine kinase inhibitor (TKI) that suppresses the activity of VEGFR, PDGFR, KIT; and plays a significant role in the second-line treatment of patients with GIST.Areas covered: This article provides an overview of data on treatment of patients with advanced GIST, with particular focus on second-line therapy. It discusses the mechanisms of resistance, the findings of key clinical trials involving sunitinib and newer TKIs, and emerging therapeutic strategies (as velzatinib and ripretinib), including combination therapies (as bezuclastinib with sunitinib), immunotherapy and new molecules. The role of circulating tumor DNA (ctDNA) is also analyzed.Expert opinion: Several drugs are currently available to enable sequential therapy in advanced disease; however, development of resistance associated with mutations in KIT and PDGFRA genes remains significant challenge. Ongoing research on new kinase inhibitors, use of ctDNA and combination therapies may in the future expand therapeutic options and enable more personalized treatment. The most probable new options that may replace sunitinib monotherapy in the second-line GIST treatment are combination of sunitinib with bezuclastinib, velzatinib, and molecularly profiled approach with ripretinib.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CURGET: a combination of common-use polyphenols plus trimetazidine as metabolic therapy for cancer: a theoretical proposal. CURGET：常用的多酚类药物加曲美他嗪作为癌症代谢疗法的组合：一个理论建议。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-17 DOI: 10.1080/14656566.2026.2749634

Pamela Pastrana-Peralta, Guadalupe Dominguez-Gomez, Adriana Romo-Pérez, Alma Chavez-Blanco, Aurora Gonzalez-Fierro, Alejandro García-Carrancá, Francisco Gutierrez-Delgado, Jose Correa-Basurto, Alfredo Cortes-Algara, Alfonso Duenas-Gonzalez

{"title":"CURGET: a combination of common-use polyphenols plus trimetazidine as metabolic therapy for cancer: a theoretical proposal.","authors":"Pamela Pastrana-Peralta, Guadalupe Dominguez-Gomez, Adriana Romo-Pérez, Alma Chavez-Blanco, Aurora Gonzalez-Fierro, Alejandro García-Carrancá, Francisco Gutierrez-Delgado, Jose Correa-Basurto, Alfredo Cortes-Algara, Alfonso Duenas-Gonzalez","doi":"10.1080/14656566.2026.2749634","DOIUrl":"10.1080/14656566.2026.2749634","url":null,"abstract":"Introduction: Repurposing inexpensive oral compounds targeting metabolic reprogramming is a pragmatic strategy. CURGET is a five-node oral regimen designed to induce metabolic starvation in tumors.Areas covered: Comprehensive literature search. The malignant phenotype features concurrent upregulation of glycolysis (HK2), glutaminolysis (GLS1), de novo lipogenesis (FASN), the mevalonate pathway (HMGR), and fatty-acid β-oxidation (FAO/3-KAT). CURGET combines four widely available polyphenols and a common cardiac drug: curcumin, urolithin A, resveratrol, EGCG, and trimetazidine to target these five enzymes. Additional mechanisms include context-dependent pro-oxidant activity and epigenetic modulation such as DNMT, HDAC, and HAT inhibition linked to cofactor depletion. This review synthesizes human safety and pharmacokinetic data, plasma AUC overlap with in vitro inhibitory concentrations, knockout evidence of metabolic plasticity, and clinical co-expression of HK2, GLS1, and FASN.Expert opinion: CURGET represents a coherent, low-cost oral strategy rather than a finalized protocol. Key priorities include developing bioavailable formulations, conducting preclinical studies with defined metabolic endpoints, and early-phase pharmacokinetic and safety assessments of the combination. If CURGET shows a favorable therapeutic index, it may be most applicable to metabolically characterized tumors, including gastric, pancreatic, and selected breast cancers. Successful development could improve access to affordable metabolic adjuncts and help reduce global disparities in cancer care.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-19"},"PeriodicalIF":3.4,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New and emerging pharmacological solutions for Behçet's syndrome. 新的和新兴的药物解决方案的白塞氏综合征。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-17 DOI: 10.1080/14656566.2026.2749638

Mitsuhiro Takeno

{"title":"New and emerging pharmacological solutions for Behçet's syndrome.","authors":"Mitsuhiro Takeno","doi":"10.1080/14656566.2026.2749638","DOIUrl":"10.1080/14656566.2026.2749638","url":null,"abstract":"Introduction: Behçet's syndrome is a chronic multisystem inflammatory disease characterized by mucocutaneous lesions, ocular inflammation, and major-organ involvement. Treatment aims to prevent irreversible organ damage and maximize health-related quality of life.Areas covered: This review summarizes current therapeutic approaches based on the 2025 update of the European Alliance of Associations for Rheumatology recommendations for Behçet's syndrome. Core recommended therapies, including colchicine, glucocorticoids, apremilast, conventional immunosuppressants, and TNF inhibitors, are selected for individual organ involvement depending on severity. The updated recommendations refine treatment strategies and emphasize individualized management rather than substantially expanding therapeutic options. This review also examines emerging non-TNF biologics targeting IL-1, IL-6, IL-17, and IL-12/23, and Janus kinase inhibitors. PubMed was searched from database inception through August 2026.Expert opinion: The rarity of Behçet's syndrome and the lack of standardized assessment tools remain major obstacles to conducting high quality clinical trials. In addition, several anti cytokine therapies may be associated with organ-specific or paradoxical manifestations in Behçet's syndrome. Further evidence is required to clarify both the efficacy and safety profiles of new therapeutic agents, and prospective controlled studies will be essential to establish their roles in clinical practice.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gedatolisib after CDK4/6 inhibition in HR-Positive/HER2-negative advanced breast cancer: pharmacology, phase iii evidence, and therapeutic positioning. Gedatolisib对hr阳性/ her2阴性晚期乳腺癌的CDK4/6抑制作用：药理学，iii期证据和治疗定位

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-17 DOI: 10.1080/14656566.2026.2752126

Aziz Ullah, Muhammad Saeed Akhtar

{"title":"Gedatolisib after CDK4/6 inhibition in HR-Positive/HER2-negative advanced breast cancer: pharmacology, phase iii evidence, and therapeutic positioning.","authors":"Aziz Ullah, Muhammad Saeed Akhtar","doi":"10.1080/14656566.2026.2752126","DOIUrl":"https://doi.org/10.1080/14656566.2026.2752126","url":null,"abstract":"Introduction: Progression following CDK4/6 inhibition remains a therapeutic challenge in hormone receptor-positive, HER2-negative advanced breast cancer. Gedatolisib, an FDA-approved pan-class I PI3K/mTORC1/2 inhibitor, introduces a treatment strategy for disease without a detected PIK3CA mutation.Areas covered: This review critically evaluates gedatolisib pharmacology, clinical evidence, safety, biomarkers, and therapeutic positioning. PubMed/MEDLINE, publisher platforms, ClinicalTrials.gov, regulatory sources, and oncology conference records were searched through July 2026, with updates through September 2026. In phase III VIKTORIA-1, median progression-free survival was 9.3 versus 2.0 months with gedatolisib-fulvestrant-palbociclib versus fulvestrant (hazard ratio 0.24) and 7.4 versus 2.0 months with gedatolisib-fulvestrant versus fulvestrant (hazard ratio 0.33). Experimental regimens were not directly compared in a powered analysis. Stomatitis, metabolic toxicity, palbociclib-associated neutropenia, and weekly intravenous administration complicate treatment delivery.Expert opinion: Gedatolisib expands post-CDK4/6 treatment options, but optimal positioning requires individualized patient selection without assuming triplet superiority. Mature survival outcomes, validated predictive biomarkers, comparative sequencing evidence, and VIKTORIA-2 findings will determine its long-term clinical value.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current perspectives in the pharmacological management of cutaneous and mucosal leishmaniasis. 皮肤和粘膜利什曼病药理学管理的当前观点。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-17 DOI: 10.1080/14656566.2026.2749637

Raimunda Nonata Ribeiro Sampaio, João Vitor Matachon Viana, Fellipe Magela de Araújo, Regina Maia de Souza, Felipe Francisco Tuon, José Angelo Lauletta Lindoso, Valdir Sabbaga Amato

{"title":"Current perspectives in the pharmacological management of cutaneous and mucosal leishmaniasis.","authors":"Raimunda Nonata Ribeiro Sampaio, João Vitor Matachon Viana, Fellipe Magela de Araújo, Regina Maia de Souza, Felipe Francisco Tuon, José Angelo Lauletta Lindoso, Valdir Sabbaga Amato","doi":"10.1080/14656566.2026.2749637","DOIUrl":"https://doi.org/10.1080/14656566.2026.2749637","url":null,"abstract":"Introduction: Leishmaniasis encompass a heterogeneous spectrum of neglected tropical diseases, with clinical course and treatment outcomes strongly influenced by Leishmania species and geographic setting. Despite recent advances, their pharmacological management remains challenging.Areas covered: This review examines current therapies for cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML), focusing on their clinical efficacy, safety, mechanisms of action, and resistance. Pentavalent antimonials, amphotericin B, miltefosine, pentamidine, paromomycin, azoles, and pentoxifylline are discussed, with particular attention to the therapeutic complexity of ML and its risk of treatment failure and relapse. A narrative literature search was conducted in PubMed/MEDLINE and Scopus, covering publications from 1990 to 2026.Expert opinion: Treatment should be individualized according to parasite, disease, and host characteristics, while also considering local drug availability. In ML, long-term follow-up and sustained cure are particularly important given the potential for recurrence and irreversible tissue damage. Future progress will depend on safer and shorter regimens, molecular tools to support therapeutic decisions, and host-directed strategies.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity: oral therapy for those afraid of needles. 肥胖：针对怕针者的口服疗法。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-16 DOI: 10.1080/14656566.2026.2749645

Sandro La Vignera, Rosita A Condorelli

{"title":"Obesity: oral therapy for those afraid of needles.","authors":"Sandro La Vignera, Rosita A Condorelli","doi":"10.1080/14656566.2026.2749645","DOIUrl":"10.1080/14656566.2026.2749645","url":null,"abstract":"Introduction: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) pharmacotherapy has transformed obesity management, yet subcutaneous administration remains a barrier for patients with needle phobia. This review examines needle phobia and agoraphobia as contributors to treatment non-adherence and evaluates the evidence for oral GLP-1 RA alternatives.Areas covered: We synthesize evidence on the epidemiology of needle phobia (trypanophobia) and agoraphobia, their mechanisms and psychiatric comorbidities, real-world discontinuation rates of injectable GLP-1 RAs, and clinical efficacy data for oral semaglutide and emerging oral agents. A brief overview of the literature search methodology (PubMed/MEDLINE, Cochrane Library, ClinicalTrials.gov; searched to June 2026) is provided in the Introduction. A structured clinical decision algorithm is proposed.Expert opinion: Oral semaglutide 25 mg/day (the currently approved dose for weight management) demonstrates weight loss of similar magnitude to subcutaneous formulations across separate trials and should be considered preferentially in patients with moderate-to-severe needle phobia. Systematic needle phobia screening at obesity clinic entry, combined with a severity-based treatment algorithm integrating pharmacological and psychological approaches, is recommended to maximize equitable access to obesity pharmacotherapy.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current perspectives on the pharmacotherapeutic management of insomnia in Veterans. 退伍军人失眠的药物治疗管理现状。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-16 DOI: 10.1080/14656566.2026.2749647

Ranime Saliba, Julia Cercone, Ali A El-Solh

{"title":"Current perspectives on the pharmacotherapeutic management of insomnia in Veterans.","authors":"Ranime Saliba, Julia Cercone, Ali A El-Solh","doi":"10.1080/14656566.2026.2749647","DOIUrl":"10.1080/14656566.2026.2749647","url":null,"abstract":"Introduction: Insomnia is a highly prevalent sleep disorder among Veterans and frequently co-occurs with post-traumatic stress disorder (PTSD), depression, chronic pain, and substance use disorders.Areas covered: This review synthesizes the current evidence on pharmacological management of insomnia in Veterans with attention to guideline recommendations, veteran-specific safety considerations, and comorbidity-driven prescribing. We discuss the rationale for reducing long-term reliance on benzodiazepines and benzodiazepine receptor agonists (BZRAs) in favor of agents with more favorable long-term risk profiles. Concurrent prescribing of GABAergic hypnotics with opioids is addressed in the context of existing VA Opioid Safety Initiative policy, FDA labeling, and observational overdose data. Off-label agents such as trazodone and quetiapine continue to be widely used despite limited efficacy evidence for insomnia; their use is best reserved for cases in which better-supported options have failed.Expert opinion: Contemporary guidance places cognitive behavioral therapy for insomnia as first-line treatment, while pharmacotherapy is reserved for patients who do not respond to, cannot access, or decline behavioral treatment. The 2025 VA/DoD guideline suggests several medications when pharmacotherapy is used, including daridorexant, doxepin, eszopiclone, lemborexant, suvorexant, zaleplon, and zolpidem, and recommends against antipsychotics, benzodiazepines, and trazodone for chronic insomnia disorder.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":3.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New and emerging pharmacological treatment options for acromegaly: a 2026 update. 肢端肥大症的新出现的药物治疗选择：2026年更新。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-10-15 DOI: 10.1080/14656566.2026.2750961

Luiz Eduardo Wildemberg, Nelma Veronica Marques, Leandro Kasuki, Monica R Gadelha

{"title":"New and emerging pharmacological treatment options for acromegaly: a 2026 update.","authors":"Luiz Eduardo Wildemberg, Nelma Veronica Marques, Leandro Kasuki, Monica R Gadelha","doi":"10.1080/14656566.2026.2750961","DOIUrl":"https://doi.org/10.1080/14656566.2026.2750961","url":null,"abstract":"Introduction: Acromegaly is associated with significant morbidity, impaired quality of life (QoL), and increased mortality when uncontrolled. While current treatments achieve biochemical control in many patients, a substantial proportion remain uncontrolled or experience persistent treatment-related burdens, highlighting a need for safer, more effective, and convenient therapeutic alternatives.Areas covered: This narrative review examines current treatment modalities, the growing role of precision medicine and biomarker-guided algorithms, and newly approved or emerging pharmacological options. A comprehensive literature search was performed in Pubmed database for articles in English, including the following terms: 'acromegaly AND new treatments,' acromegaly AND new drugs,\" 'acromegaly AND CAM2029,' 'acromegaly AND paltusotine,' 'acromegaly AND debio4126,' 'acromegaly AND CAM4071,' 'acromegaly AND MAR002,' 'acromegaly AND HTL0030310,' 'acromegaly AND Hu-13H02m,' 'acromegaly AND biomarkers,' 'acromegaly AND precision medicine,' 'acromegaly AND personalized treatment.' This review highlights innovations such as long-acting subcutaneous octreotide depots (CAM2029), oral selective somatostatin receptor type 2 agonists (paltusotine), extended-interval formulations (Debio 4126), subcutaneous pasireotide depots (CAM4071), allosteric growth hormone receptor antagonists (MAR002), and direct growth hormone-neutralizing antibodies.Expert opinion: Integrating personalized medicine approaches with novel pharmacological agents offering greater convenience and distinct mechanisms of action holds significant promise for overcoming current treatment limitations, optimize biochemical control, and enhance patient well-being.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0